"The Cerêve Sleep System, a prescription device that helps reduce latency to stage 1 and stage 2 sleep by keeping the forehead cool has received US Food and Drug Administration (FDA) commercial clearance for use in patients with insomnia, the comp"...
ProSom (estazolam) is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both outpatient studies and a sleep laboratory study have shown that ProSom (estazolam) administered at bedtime improved sleep induction and sleep maintenance (see CLINICAL PHARMACOLOGY).
Because insomnia is often transient and intermittent, the prolonged administration of ProSom (estazolam) is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered.
There is evidence to support the ability of ProSom (estazolam) to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY).
DOSAGE AND ADMINISTRATION
The recommended initial dose for adults is 1 mg at bedtime; however, some patients may need a 2 mg dose. In healthy elderly patients, 1 mg is also the appropriate starting dose, but increases should be initiated with particular care. In small or debilitated older patients, a starting dose of 0.5 mg, while only marginally effective in the overall elderly population, should be considered.
ProSom (estazolam) tablets are scored tablets supplied as:
ProSom (estazolam) Tablets 1 mg white tablets bearing the Abbott logo and UC (Abbo-Code).
Bottles of 100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (NDC 0074-3735-13)
ProSom (estazolam) Tablets 2 mg pink tablets bearing the Abbott logo and UD (Abbo-Code).
Bottles of 100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (NDC 0074-3736-13)
Recommended storage: Store below 86°F (30°C).
Revised: December, 2004. Mfd. by Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617. FDA revision date: 6/4/2004This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/19/2008
Additional Prosom Information
Prosom - User Reviews
Prosom User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.